Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2049-2054

  Ohie, Shinji ^a   Udagawa, Yasuhiro ^a   Kozu, Akiko ^a   Komuro, Yuki ^a   Aoki, Daisuke ^a   Nozawa, Shiro ^a   Moossa, A R ^b   Hoffman, Robert M ^b,c  

^a KEIO UNIVERSITY   (Japan)

^b ANTICANCER INC   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cisplatin; Clinical correlation; Cyclophosphamide; Doxorubicin; Histoculture drug response assay; Ovarian cancer

Indexed keywords

CISPLATIN; COLLAGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ARTICLE; ASSAY; CELL VIABILITY; CORRELATION FUNCTION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0033884312     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Carter SK: Cisplatin-past, present and future. Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff Publishing, 1984, p. 359-376.
2. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57: 1725-1730, 1986.
3. Yakushiji M, et al: Current view of chemotherapy for advanced ovarian cancer. Karkinos 9 (Vol. 7, No. 9), 1994.
4. Petterson F, ed: In: Annual Report on the Results of Treatment in Gynecological Cancer. In Gynecol Obstet 36: 239-269, 1991.
5. Hamburger AW, Salmon SE Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
6. Salmon SE, Hamburger AW, Soehnlen BJ, Durie BG, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321-1327, 1978.
7. Alberts DS, Salmon SE, Chen HSG, Surwit EA, Soehnlen B, Young L, Moon TE: In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2: 340-342, 1980.
8. Inoue, K: Chemotherapy testing for human ovarian cancer using in vitro colony assay. Jpn J Cancer Chemother 12: 1593-1598, 1985.
9. Von Hoff DD: He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 82: 96-101, 1990.
10. Freeman AE and Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83: 2694-2698, 1986.
11. Vescio RA, Redfern CH, Nelson TJ, et al. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1987.
12. Hoffman, RM, Connors, KM, Meerson-Monosov, AZ, et al: A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro. Proc Natl Acad Sci USA 86: 2013-2017, 1989.
13. Vescio, RA, Connors KM, Kubota T, et al: Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci USA 88: 5163-5166, 1991.
14. Hoffman, RM: Three-dimensional histoculture: Origins and application in cancer research. Cancer Cells 3: 86-92, 1991.
15. Furukawa T, Kubota T, Watanabe M, et al: High in vitro-in vivo correlation of drug response using sponge gel-supported three-dimensional histoculture and the MTT end point. Int. J. Cancer 51: 489-498, 1992.
16. Furukawa T, Kubota T, Watanabe M, et al: Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point. Anticancer Res 12: 1377-1382, 1992.
17. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305-311, 1995.
18. Tobias JS, Griffiths, CT: Management of ovarian carcinoma: Current concepts and future prospects. N Engl J Med 294: 818-822, 1976.
19. Furukawa T, Kubota T, Watanabe M, et al. Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix. J Surg Oncol 49: 86-92, 1992.
20. Maehara Y, Anai H, Tamada R, Sugimachi K: The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 23: 273-276, 1987.
21. Kubota T, Sasano N, Abe O et al: Potential of the histoculture drug response assay to contribute to cancer patient survival. Clinical Cancer Res 1: 1537-1543, 1995.